Currently Browsing

Product News

Aurobindo Receives FDA Approval for Emtricitabine Capsules, 200 mg

Published: March 15, 2023

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Emtricitabine Capsules, 200 mg. Aurobindo Pharma’s Emtricitabine Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Emtriva® (emtricitabine) Capsules manufactured by Gilead Sciences, Inc.

Emtricitabine Capsules are indicated in:

  • Combination with other antiretroviral agents, for the treatment of HIV-1 infection.